SpyGlass Pharma has raised $75 million in a Series D funding round led by Sands Capital to further its Drug Delivery Platform for glaucoma patients.
SpyGlass Pharma has raised $75 million in a Series D funding round led by Sands Capital to further its Drug Delivery Platform for glaucoma patients.
06/02/25, 12:15 PM
Location
aliso viejoMoney raised
$75 million
Industry
health care
Round Type
series d
Investors
Vertex Ventures Hc, Samsara Bio Capital, Vensana Capital, Ra Capital, New Enterprise Associates (Nea), Gilde Healthcare, Sands Capital
SpyGlass Pharma, an ophthalmic biotechnology company, confirmed a $75 million Series D financing round. This funding will aid in advancing their Drug Delivery Platform through two Phase III pivotal trials. The round was joined by Gilde Healthcare and existing investors. CEO Patrick Mooney expressed gratitude for investor support, highlighting the commitment to addressing unmet needs in ophthalmic patient care.
Company Info
Location
27061 aliso creek road
aliso viejo, california, united states
Additional Info
SpyGlass Pharma was Co-founded by Dr. Malik Y. Kahook, MD and Glenn Sussman. The company is focused on the development of novel treatments for chronic ophthalmic diseases based on technology originally developed in the Sue Anschutz-Rodgers Eye Center of the University of Colorado School of Medicine.